Parse Biosciences, the leader in scalable single-cell sequencing solutions, announced the expansion of its Evercode BCR product line to support applications in mice. The new kit enables researchers to analyze the mouse BCR gene repertoire as well as whole transcriptome data from millions of cells in a single experiment, providing unparalleled scale and efficiency for antibody discovery.
The Evercode BCR platform is designed to simplify the workflow of antibody research, enabling scientists to identify individual antibody-producing cells and their associated clonal cell populations that produce specific target antibodies. Its unique features, such as sample fixation, allow researchers to preserve mouse cells and samples for up to six months, thereby reducing the need for additional experimental mice and maximizing the output of each discovery study. In addition, the technology does not require expensive equipment and can perform advanced single-cell analysis using standard laboratory tools.
Evercode BCR is able to comprehensively analyze the diversity of BCR clonotypes and the frequency of VDJ gene usage, while its high pairing rate with immunoglobulin heavy and light chains ensures the accuracy of antibody analysis. In addition, the platform excels in detecting rare cell populations (such as plasma cells) preserved by gentle fixation and advanced combined cell barcoding technology.
Also Read: Resilience Names William S. Marth as CEO
“With the expansion of Evercode BCR’s capabilities to support mouse studies, researchers can fully characterize immunological responses in disease-specific mouse models to accelerate antibody discovery efforts,” said Charlie Roco, CTO and co-founder of Parse Biosciences. “We are excited to see the impact this technology will have on the field of immunology and antibody-based drug discovery as a whole.”
Dan Rohrer, CTO of AbTherx, an early user, praised the product’s potential: “We are excited to see the first successful application of Evercode BCR in transgenic mouse B cell analysis. We believe that the Parse kit and technology will enable deep mining of the Atlas™ B cell lineage and compartmental analysis, providing superior performance in antibody discovery and diversity studies.”
Parse Biosciences is a global life sciences company whose mission is to accelerate human health and scientific research. The company enables researchers to perform single-cell sequencing at unprecedented scale and convenience, enabling groundbreaking advances in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system through innovative experimental approaches.
SOURCE: Businesswire